Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "biosimilar"

236 News Found

Lupin receives Health Canada approval for Rymti
Drug Approval | September 14, 2022

Lupin receives Health Canada approval for Rymti

Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis


US FDA issues 17 observations for Biocon Biologics sites
News | September 01, 2022

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools


Novartis to spin-off Sandoz business to a standalone company
News | August 28, 2022

Novartis to spin-off Sandoz business to a standalone company

Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US


Biocon Sdn. Bhd. enters Malaysia Book of Records
Biotech | August 08, 2022

Biocon Sdn. Bhd. enters Malaysia Book of Records

The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR


Thermo Fisher to expand dry powder media manufacturing facility in New York
News | August 05, 2022

Thermo Fisher to expand dry powder media manufacturing facility in New York

With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies


Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
News | June 24, 2022

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.


Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation
News | June 18, 2022

Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation

Both manufacturing facilities are based out of Benguluru, India


Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation
Drug Approval | June 16, 2022

Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation

Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation


Biocon Biologics and Viatris launch Abevmy in Canada
Drug Approval | May 19, 2022

Biocon Biologics and Viatris launch Abevmy in Canada

Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020